Research

Macro partitioning

Orlistat, a pancreatic lipase inhibitor, promotes modest weight loss and improves gut microbiota diversity (increasing Akkermansia and Verrucomicrobia), but its efficacy is significantly lower than GLP-1 agonists.

Orlistat blocks fat absorption, leading to modest weight loss and improved gut bacteria diversity. However, it is significantly less effective than GLP-1 agonists. Side effects like bloating and diarrhea are common if dietary fat is not strictly limited.

ModerateQualifiesMEDIUM confidence
Orlistat appears to influence microbiotal diversity by increasing the abundance of Verrucomicrobia and Akkermansia... On the other hand, the effect of orlistat is lower than the recent incretin analogues
Karolina Zarówna et al. · International Journal of Innovative Technologies in Social Science · 2026

Why this rating

Based on clinical trials and meta-analyses, but effect size is smaller.

Source

PHARMACOLOGICAL AND SURGICAL TREATMENT OF OBESITY: INTEGRATING THE ROLES OF INFLAMMATION AND GUT DYSBIOSIS- REVIEW

Karolina Zarówna et al. · International Journal of Innovative Technologies in Social Science · 2026

DOI 10.31435/ijitss.1(49).2026.4791

narrative_review
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →